idarucizumab (Praxbind) -

idarucizumab (Praxbind)
Information type: Guidance
Source: Scottish Medicines Consortium
Specialities: Cardiovascular system disorders | Haematological disorders
Summary
The SMC has accepted for use within NHS Scotland, idarucizumab (Praxbind®) for adults treated with dabigatran etexilate, when rapid reversal of its anticoagulant effects is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.
UKMi comment
NICE has previously published an evidence summary looking at the evidence for the efficacy and safety of idarucizumab for reversing the anticoagulant effect of dabigatran etexilate.
Related links: NICE evidence summary